TON September 2015 Vol 8 No 5

Antibody-drug conjugates (ADCs) offer a unique approach for the treatment of solid tumors and hematologic cancers. The idea is that a potent cytotoxic agent is linked to an antibody specifically targeted to tumor cells, and once the antibody binds to the tumor cell, the cytotoxic agent is unleashed inside the cells to attack the cancer. Read More ›

Treatment for chronic lymphocytic leukemia (CLL) has come a long way with the availability of new drugs that improve outcomes. As new treatments become available, there is a corresponding learning curve. Read More ›

Approximately 40% of patients treated with anthracyclines are still not receiving National Comprehensive Cancer Network (NCCN) guideline–adherent prophylaxis for chemotherapy-induced vomiting. Read More ›